| abstract |
The present invention provides a compound of the formula (I) wherein R 1 is —H, —OH, —O(C 1 –C 4 alkyl), —OCOC 6 H 5 , —OCO(C 1 –C 6 alkyl), or —OSO 2 (C 2 –C 6 alkyl); R 0 , R 2 and R 3 are each independently —H, —OH, —O(C 1 –C 4 alkyl), —OCOC 6 H 5 , —OCO(C 1 –C 6 alkyl), —OSO 2 (C 2 –C 6 alkyl) or halo; R 4 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino; n is 2 or 3; X is S— or —HC═CH—; and Y is O—, —S—, —NH—, —NMe—, or —CH 2 —; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions thereof, optionally in combination with estrogen and progestin; methods of inhibiting a disease associated with estrogen deprivation; and methods for inhibiting a disease associated with an aberrant physiological response to endogenous estrogen |